$16.13
0.06% yesterday
Nasdaq, Sep 03, 10:16 pm CET
ISIN
US87164F1057
Symbol
SNDX

Syndax Pharmaceuticals Inc Stock price

$16.13
+5.75 55.40% 1M
+0.65 4.20% 6M
+2.91 22.01% YTD
-4.41 21.47% 1Y
-8.12 33.48% 3Y
+0.54 3.46% 5Y
+4.12 34.30% 10Y
+4.12 34.30% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.01 0.06%
ISIN
US87164F1057
Symbol
SNDX
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.3b
Net debt
positive
Cash
$468.7m
Shares outstanding
86.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
17.8 | 8.6
EV/Sales
16.2 | 7.8
EV/FCF
negative
P/B
8.8
Financial Health
Equity Ratio
39.8%
Return on Equity
-110.6%
ROCE
-70.2%
ROIC
-
Debt/Equity
2.2
Financials (TTM | estimate)
Revenue
$78.2m | $162.4m
EBITDA
$-339.1m | $-316.8m
EBIT
$-339.1m | $-313.3m
Net Income
$-335.0m | $-282.0m
Free Cash Flow
$-302.7m
Growth (TTM | estimate)
Revenue
2,133.7% | 585.7%
EBITDA
-17.7% | 6.7%
EBIT
-17.7% | 7.8%
Net Income
-26.9% | 11.5%
Free Cash Flow
-25.5%
Margin (TTM | estimate)
Gross
80.2%
EBITDA
-433.7% | -195.1%
EBIT
-433.7%
Net
-428.5% | -173.7%
Free Cash Flow
-387.1%
More
EPS
$-3.9
FCF per Share
$-3.5
Short interest
27.0%
Employees
270
Rev per Employee
$90.0k
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
78 78
2,134% 2,134%
100%
- Direct Costs 2.99 2.99
-
4%
63 63
-
80%
- Selling and Administrative Expenses 154 154
67% 67%
197%
- Research and Development Expense 260 260
31% 31%
333%
-339 -339
18% 18%
-434%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -339 -339
18% 18%
-434%
Net Profit -335 -335
27% 27%
-428%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
about 22 hours ago
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division P...
Neutral
GlobeNewsWire
8 days ago
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Positive
Seeking Alpha
21 days ago
Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo launch in chronic GVHD. Incyte is the ideal partner for GVHD, being highly familiar with this space and the 50/50 split in the US provides a significant downside cushion to investors.
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today